Loading
A phase 2 trial of nab-paclitaxel and gemcitabine in pancreatic cancer, run by Fudan University, now recruiting.
PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients is a phase 2, interventional study registered as NCT06359275 by Fudan University, with a registry enrolment figure of 81 participants, started 2024-06-01 and due to reach its primary completion in 2025-12. Interventions recorded: PD-1; Nab-paclitaxel; Gemcitabine; PULSAR. Conditions listed: Pancreatic Cancer. Primary outcome: Progression-free survival (PFS). Pancreatic eligibility wording from the registry: "Locally advanced pancreatic adenocarcinoma confirmed by histopathology or cytology, or pancreatic cancer with only local recurrence but no distant metastasis after surgery (local recurrence includes tumor bed recurrence and regional lymph node metastasis, which needs to be confirmed by biopsy pathol". Sites: China. No results are recorded here; the registry entry is the source.
Shares Nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.